US Patent

US8791127 — Mucosal bioadhesive slow release carrier for delivering active principles

Method of Use · Assigned to Bioalliance Pharma SA · Expires 2027-03-23 · 1y remaining

Vulnerability score 85/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a mucosal bioadhesive slow release carrier for delivering active principles for a duration of longer than 20 hours.

USPTO Abstract

A mucosal bioadhesive slow release carrier comprising an active principle and devoid of starch, lactose, which can release the active principal for a duration of longer than 20 hours. This bioadhesive carrier contains a diluent, an alkali metal alkylsulfate, a binding agent, at least one bioadhesive polymer and at least one sustained release polymer, as well as a method for its preparation.

Drugs covered by this patent

Zovirax (ACYCLOVIR) · Ligand Pharms

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1460`	—	Zovirax

Patent Metadata

Patent number: US8791127
Jurisdiction: US
Classification: Method of Use
Expires: 2027-03-23
Drug substance claim: No
Drug product claim: Yes
Assignee: Bioalliance Pharma SA
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.